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Abstract 
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well under-
stood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where 
alternate therapies are lacking. We recently published a paper entitled “Co-option of liver vessels and not sprouting 
angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma” in the Journal of the National Cancer 
Institute, providing a potential explanation for this limited benefit. We found that in mice bearing HCCs that had 
acquired resistance to sorafenib, tumors had switched from using angiogenesis for growth to co-opting the liver vas-
culature by becoming more invasive. Accumulating evidence suggests that many human tumor types may use vessel 
co-option, which has profound implications for the use of anti-angiogenic agents for cancer treatment.
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Background
Advanced hepatocellular carcinoma (HCC) is difficult to 
treat. It is a highly aggressive tumor, intrinsically resistant to 
conventional anti-cancer therapies such as chemotherapy 
and irradiation. Treatment options were bleak until 8 years 
ago when the oral kinase inhibitor sorafenib (Nexavar) 
was approved for advanced HCC treatment, yet sorafenib 
remains the only approved systemic drug treatment.
Sorafenib is a selective inhibitor of vascular endothe-
lial growth factor receptor 2 (VEGFR2), platelet-derived 
growth factor receptor (PDGFR), and Raf kinases, and 
its anti-tumor mechanism includes stromal effects such 
as anti-angiogenesis and direct anti-proliferative and 
pro-apoptotic effects on tumor cells [1]. HCCs are hyper-
vascular tumors. However, the durability of response to 
sorafenib is limited, with median extensions in overall 
survival of 2–3 months and single-digit response rates [2, 
3]. Other more potent or specific VEGF-targeted agents 
have been proved to be no better than sorafenib in ran-
domized phase II or III clinical trials or have failed  to 
improve outcomes as second-line therapy [4]. Sorafenib 
resistance therefore remains a major clinical challenge, 
which cannot be controlled by anti-VEGF pathway angi-
ogenesis inhibitors alone.
Vessel co‑option as a resistance mechanism
In our study “co-option of liver vessels and not sprout-
ing angiogenesis drives acquired sorafenib resistance 
in hepatocellular carcinoma” recently published in the 
Journal of the National Cancer Institute [5], we proposed 
a new explanation for why the anti-tumor effects of 
sorafenib on HCC may be short-lived and why alternate 
anti-VEGF agents, especially as second-line therapies, are 
not helping (Fig. 1). We found that orthotopically grown 
HCCs in immune-compromised mice were highly angio-
genic and that daily sorafenib treatment initially potently 
depleted angiogenic vessels and significantly slowed 
tumor progression. However, tumors began to manifest 
signs of drug resistance after being treated for a month. 
At this time, tumor cells began to grow in a highly inva-
sive manner but did not induce new blood vessel growth. 
Rather, the tumor cells had surrounded the sinusoi-
dal and major vessels of the liver and incorporated 
them into its mass. Since these liver vessels that were 
hijacked by the tumor (“co-opted” from the host) were 
originally “normal” vessels, they could not be blocked by 
sorafenib treatment. Only when sorafenib treatment was 
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discontinued, tumors showed fewer signs of invasion and 
switched back to relying on angiogenesis.
The finding that certain tumors can grow along and co-
opt the normal tissue vasculature without inducing neo-
angiogenesis has been under-appreciated, if not ignored. 
Vessel co-option has been found to be a mode of vasculari-
zation in several human tumor types which grow in vessel-
rich organs, including the brain, lungs, and liver [6]. These 
organs offer an appealing environment for tumor growth 
due to a high oxygen and nutrient supply. Certain tumors 
innately “prefer” using angiogenesis over co-option, or the 
converse, and others use both vascular mechanisms simul-
taneously. Vessel co-option may be important at early stages 
of HCC progression prior to induction of capillarization 
(angiogenesis) [7] and in well-differentiated HCCs in which 
vessels have been found to express markers of sinusoidal 
liver endothelial cells [8]. In the absence of anti-angiogenic 
treatment, advanced HCCs were found to have growth 
patterns consistent with vascularization through either 
angiogenesis by growing as encapsulated masses, or ves-
sel co-option by infiltrating the sinusoids or replacing the 
hepatic cords [9]. There is therefore a strong possibility that 
depleting angiogenic vessels could cause an HCC to switch 
to dependence on the co-opted liver vessels. Potentially, 
some HCC patients may be resistant to sorafenib upfront 
because their tumors use mostly co-option, or, as we 
observed in mice, their tumors switch to this mechanism.
Treatment‑induced invasion and EMT
The role of vessel co-option during sorafenib resistance 
may be connected to the finding that, in certain situ-
ations, treatment of mice with anti-angiogenic agents 
can render cancer cells more invasive and metastatic 
[10, 11]. This may occur secondary to increased hypoxia 
in tumors caused by the anti-angiogenic effects of the 
drug. For example, increased rates of metastasis and 
local tumor cell invasion were observed in pancreatic 
neuroendocrine tumor- and glioblastoma-bearing mice 
after treatment with anti-VEGFR2 monoclonal antibody 
or sunitinib [11]. This occurred despite primary tumor 
shrinkage and depletion of angiogenic vessels, similar 
to what we observed in HCCs during sorafenib treat-
ment. One could speculate that during anti-angiogenic 
treatment, the invading fronts of such tumors contained 
instead the co-opted  local vessels of the pancreas and 
brain, but this is currently unknown.
Further underscoring the mechanism that increased 
HCC invasion precipitated vessel co-option, we used 
microRNA screening and reverse transcription-polymer-
ase chain reaction to find that the epithelial-to-mesen-
chymal transition (EMT) pathway corresponded to the 
onset of invasion in HCC tumors [5]. EMT is considered 
an important pathway for the early steps of tumor inva-
sion and metastasis, during which tumor cells lose their 
polarity, adopt a mesenchymal morphology, and become 
more motile [12]. EMT has previously been proposed as 
a mechanism of sorafenib resistance in HCC cells in vitro 
by gradually increasing the concentration of sorafenib 
over months [13, 14]. Thus, resistant HCC cells appeared 
mesenchymal, up-regulated several EMT genes, were 
more invasive and more metastatic once implanted into 
mice relative to parental cell lines [13, 14]. By in  vivo 
treatment, we observed significant changes in vimen-
tin, Zeb1/2, and E-cadherin expression, but HCC cells 
Fig. 1 Proposed mechanism of acquired resistance to the multikinase inhibitor sorafenib in hepatocellular carcinoma (HCC). Highly angiogenic 
HCCs are initially responsive to sorafenib treatment. Over time, tumor cells become more invasive which promotes co-option of liver vessels in the 
face of angiogenesis blockade. EMT epithelial-to-mesenchymal transition
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remained epithelial in morphology and were not more 
metastatic. The apparent differences in the behavior of 
HCC cells between in  vivo and in  vitro treatments of 
HCC, the latter involving more prolonged treatment and 
supra-physiologic drug concentrations, are notable when 
considering the translation of these findings to the clinic.
The pro-invasive/metastatic effects observed in mice 
have caused some debates because accelerated disease 
progression (such as an increased rate of metastasis) has 
not been observed in large follow-up studies of patients 
treated with sunitinib or bevacizumab [15, 16]. These 
conflicting clinical/preclinical results could be explained 
if a major consequence of anti-angiogenic treatment-
induced invasion is not metastasis, but rather  an 
increased tumor reliance on vessel co-option. The above 
clinical studies unfortunately cannot inform on potential 
pro-invasive effects that occur on-treatment because data 
was collected long after anti-angiogenic therapy discon-
tinuation [17] and potential reversal of vascular changes.
Future research
Specific molecular markers of co-opted vessels are pres-
ently unknown. Therefore, histological analyses of tumor 
growth patterns as well as expression of angiogenic and 
tissue-specific endothelial and epithelial cell markers are 
necessary for insight into the occurrence of vessel co-
option in tumors. Such analyses of the vascular pheno-
type during long-term sorafenib treatment of HCCs are 
highly deficient. Rather, in vitro studies of HCC cell lines 
predominate the literature [18] which disregards the stro-
mal effects of sorafenib.
Our finding needs to be confirmed in HCC patients. 
The procurement of patient tumor specimens of suffi-
cient volume while a patient is on anti-angiogenic ther-
apy is a major challenge but is highly needed. We are 
aware of a single report in which biopsies of an HCC 
patient’s tumor obtained prior to and during disease 
progression on sorafenib were screened for resistance 
mechanisms. Proteomic and phospho-proteomic analy-
sis strongly implicated EMT and anti-adhesive signaling 
during sorafenib treatment or resistance [19]. Further 
hints that vessel co-option mediates clinical resistance to 
anti-angiogenic therapy was published very recently in 
a retrospective study, in which a “replacement” growth 
pattern involved co-option of vessels with poor clinical 
responses to bevacizumab in liver metastases [20].
Vessel co-option is increasingly realized as a major 
blood supply for tumors which have crucial implica-
tions for therapy selection. If vessel co-option is proved 
to be a cause of clinical drug resistance in HCC, the use 
of “anti-vascular” rather than anti-angiogenic therapies 
will be an important therapeutic strategy going forward. 
Drugs which block or inhibit tumor cell invasion when 
this process is known to precede a switch to vessel co-
option by tumors, may be evaluated as an alternative 
therapy.
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